Caas Capital Management LP Mirati Therapeutics, Inc. Transaction History

Caas Capital Management LP

  • $836 Million
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 16, 2021
SELL
$144.0 - $179.73 $16.7 Million - $20.8 Million
-115,829 Closed
0 $0
Q1 2021

May 17, 2021
BUY
$158.92 - $221.61 $18.4 Million - $25.7 Million
115,829 New
115,829 $19.8 Million
Q3 2020

Nov 09, 2020
SELL
$113.26 - $167.27 $29.2 Million - $43.1 Million
-257,928 Closed
0 $0
Q2 2020

Aug 14, 2020
BUY
$72.01 - $120.39 $18.6 Million - $31.1 Million
257,928 New
257,928 $29.4 Million

Others Institutions Holding MRTX

# of Institutions
16
Shares Held
3.57M
Call Options Held
0
Put Options Held
36.6K
View Full List

About Mirati Therapeutics, Inc.

MRTX Quotes by TradingView
  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Caas Capital Management LP Portfolio

Follow Caas Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caas Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Caas Capital Management LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email